Acipimox Acutely Increases GLP-1 Concentrations in Overweight Subjects and Hypopituitary Patients.

ABSTRACT:

Context

Glucagon-like peptide-1 (GLP-1) is an incretin hormone used therapeutically in type 2 diabetes and obesity. The interplay between ambient free fatty acids (FFAs) and GLP-1 remains unclear. Acipimox suppresses adipose tissue lipolysis via activation of the PUMA-G (also known as HCA2 and GPR109a) receptor.

Objective

To investigate whether lowering of serum FFA level with acipimox affects GLP-1 secretion.

Design

Two randomized crossover studies were performed in human subjects. Rat intestine was perfused intra-arterially and intraluminally, and l-cells were incubated with acipimox.

Participants

The participants were healthy overweight subjects and hypopituitary adult patients.

Interventions

The overweight participants received acipimox 250 mg 60 min

SUBMITTER: Vestergaard ET 

PROVIDER: S-EPMC7212086 | biostudies-literature | 2019 Jul

REPOSITORIES: biostudies-literature